Briacell Therapeutics Corp (NASDAQ: BCTX) announced that recruitment and enrolment are open for its advanced breast cancer trial. The company is performing the study in partnership with Incyte. The Phase I/IIa combination study is designed to evaluate BriaCell’s lead candidate, Bria-IMT™, with Incyte’s checkpoint inhibitor, retifanlimab, and IDO1 inhibitor, epacadostat, […]
Tag: BriaCell Therapeutics Corp (NASDAQ: BCTX)
BriaCell Therapeutics Corp (NASDAQ: BCTX) Jumps 6.5% After Announcing Expansion of Its Breast Cancer Platform Tech
BriaCell Therapeutics Corp (NASDAQ: BCTX) jumped 6.51% after the company announced its targeted oncology therapy advancement into other novel immunotherapy cell lines: Bria-Mel for melanoma Bria-lung for lung cancer, and Bria-Pros from Prostate cancer. BriaCell developing personalized cancer immunotherapies The company’s immunotherapy treatment seemed to be effective in breast cancer […]